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Inactivation of the transcription factor/tumor sup-
pressor Krüppel-like factor 6 (KLF6) has been de-
scribed in prostate cancer (PC). This study investi-
gated the prevalence and significance of KLF6 exon 2
mutations and splice variants (SVs) in different stages
of human PC progression. By using laser-capture mi-
crodissection and recombinant clone isolation of
DNA sequences to enhance sensitivity, base changes
were found in 20 (24.7%) of 81 PC tissues versus 1
(4%) of 25 normal prostate tissues (P  0.02). Of 26
base changes, 54% produced nonsynonymous muta-
tions. Only three mutations had driver characteristics
(PCs, 4%; NPs, 0%). By using microdissection of fresh-
frozen tissues and recombinant isolation of RNA se-
quences, SVs were found in 39 (75%) of 52 PCs and in
10 (45%) of 22 NPs (P  0.01). Sixteen different SVs,
including 13 unique SVs, were identified that used
cryptic splicing sites and encoded nonfunctional
KLF6 proteins. PCs that had survived hormone (an-
drogen)-deprivation therapy (n  21) had a signifi-
cantly higher (P < 0.05) incidence, number, and ex-pression level of nonfunctional SVs than either NPs
(n 22) or hormone-naïve PCs (n 25). Forced expres-
sion of nonfunctional SVs conferred a survival advan-
tage of androgen-dependent LNCaP cells under castra-
tion-simulated culture conditions. Together, these data
suggest that decreased availability of functional KLF6
contributes to clinical PC progression. This decrease
arises infrequently by somatic mutation and more com-
monly by the acquisition of SVs that provide a survival
advantage under castrate conditions, enabling resis-
tance to hormone therapy. (Am J Pathol 2012, 181:1007–
1016; http://dx.doi.org/10.1016/j.ajpath.2012.06.008)
Krüppel-like factor 6 (KLF6) is a ubiquitously expressed
member of a large family of mammalian Sp1/KLF tran-
scription factors that play a critical role in the regulation of
cellular development, differentiation, proliferation, and
apoptosis.1 Some of the best known transcriptional tar-
gets of KLF6 include p21, E-cadherin,2 and ATF3.3 The
KLF6 gene is located on chromosome arm 10p and has
four exons that encode a protein with 283 amino acids
(AAs), including a transactivation domain (TAD) and
three zinc fingers (ZFs) that constitute the DNA-binding
domain (DBD).4,5
A potential role for KLF6 in cancer emerged when a
study of 22 localized prostate cancer (PC) specimens
showed that 55% of the tumor cells had loss of heterozy-
gosity.6 Furthermore, in specimens with loss of heterozy-
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ing allele. Of 30 total KLF6 mutations identified in these
tumors, 28 (93%) were in exon 2 and 24 (86%) changed
the AA sequence, whereas no mutations were found in a
subset of matched normal epithelial counterparts (NECs).
In addition, mutant KLF6 constructs were unable to trans-
activate p21 and augmented PC cell proliferation. These
results supported the notion that KLF6 is a tumor sup-
pressor gene frequently inactivated by somatic mutations
in PC. However, these results were not confirmed in three
subsequent studies, one of which found exon 2 base
change (BC) in 10 (13%) of 75 PC specimens7 and two of
which found no exon 2 BC in 135 PC specimens.8,9
Another mechanism for decreasing the availability of
functional KLF6 is by altering the expression of splice
variants (SVs). Alternative splicing has been detected in
several solid tumors, including PCs.10–14 In primary PC
tissues, three KLF6 SVs involving different areas of the
TAD and the ZF were identified.10 In addition, men with a
germline single-nucleotide polymorphism located in in-
tron 1 (27 GA) were at increased risk of PC.11 This
single-nucleotide polymorphism, found in 15.1% of spo-
radic PCs, generates a novel DNA-binding site for splic-
ing factors that generate three alternatively spliced KLF6
isoforms in vitro, SV1 through SV3. In 15 PC specimens,
the expression of KLF6 spliced isoforms was twofold
higher than that of wild-type (wt) KLF6 mRNA compared
with six normal prostate (NP) specimens. No differences
in SV2 and SV3 expression were observed between pri-
mary PC tumors and metastases.10,11
SV1 through SV3 have been characterized in some
detail. SV1 lacks part of the TAD and all three ZFs, SV2
has a partial loss of the TAD and ZF1 but retains ZF2 and
ZF3, and SV3 lacks ZF2 and ZF3 but preserves an intact
TAD and ZF1.5 Functional analysis indicated that SVs
lacking ZF1 lose the nuclear localizing signal and remain
cytoplasmic, whereas SVs that retain ZF1 localize to the
nucleus, such as wt-KLF6, irrespective of the status of
ZF2 and ZF3.5 In vitro assays showed that forced expres-
sion of SV1 in PC cells increased proliferation by antag-
onizing wt-KLF6 activity and decreasing endogenous
p21 levels.11 In contrast, in vivo overexpression of SV1 in
PC3M xenografts did not affect local tumor growth, but it
enhanced angiogenesis and metastases.10 The func-
tional activity of SV2 is unclear. Although some investiga-
tors found that overexpressed SV2 in PC3 cells remained
cytoplasmic and was unable to induce p21, other groups
found that SV2 induced endogenous p21 and ATF3 tran-
scription and produced apoptosis.3,12 In one study, SV3
localized to the nucleus, but functional analysis was not
performed.5
Collectively, the data previously summarized suggest
that local (cis) changes in exon or intron gene sequences
alter the availability of functional KLF6 and may play a
role in PCs. However, the apparent prevalence of muta-
tions significantly differs among human PC studies, and
the prevalence of splicing has not been established,
making the significance of either unclear. The main goals
of this study were to more incisively assess the preva-
lence of KLF6 exon 2 mutations and alternative KLF6
mRNA splicing in human PC progression. In addition,because mRNA splicing is highly regulated and respon-
sive to environmental conditions,13 we evaluated whether
it might play a role in tumor cell adaptation to castrate
conditions.
Materials and Methods
Tumor Samples and Patients
Human tissue specimens from patients who consented
were obtained from the tissue banks of the Department
of Pathology, Mount Sinai Hospital, New York, NY;
Stadtische Klinikum Frankfurt am Main, Offenbach, Ger-
many; New York University Cooperative Prostate Cancer
Tissue Resource & Prostate Cancer Serum and Genetics
Repository; and the National Disease Research Inter-
change.14 Except for the latter, all samples were consecu-
tively collected. This study (CA098135-010) was approved
by the Institutional Review Boards at Mount Sinai School of
Medicine (020137) and New York University (numbers 1245
and 8723). In total, 159 samples were processed, including
116 primary PCs (Gleason score of 6, 72%; score of 7, 9%;
score of 8, 14%; score of 9, 1%; and score of 10, 4%), 18
NECs, 14metastases (mets), and 29NPs from cadavers. Of
the 116 PCs, 70 (18 with associated NECs) were formalin
fixed, paraffin embedded (FFPE), and 46 were frozen in
liquid nitrogen. Of the 14 mets, eight were FFPE hormone-
naïve lymph nodes (HN-LNs) and six were frozen castra-
tion-resistant PC (CRPC) mets from bone marrow,2 skull,
epidural mass, and peritoneal/pleural effusion cells. All 29
NPs were frozen samples.
KLF6 Exon 2 Mutation Analysis
Tissue Processing and Nucleic Acid Extraction
Sections of FFPE specimens (8 to 10 m thick) were
mounted on 10to 20 superfrost/snow-treated slides (Fisher
Scientific, Pittsburgh, PA) and stained with Mayer’s H&E to
map 5000 cells of each PC and NEC. Sections were
processed by a standard deparaffinization/dehydration-re-
hydration protocol and stained with hematoxylin for laser-
capture microdissection (LCM). Sections of frozen speci-
mens (7 to 15 m thick) in Tissue-Tek OCT (Fisher
Scientific) were processed on RNase-free superfrost/snow-
treated slides (Fisher Scientific). LCM was performed using
the Pixcell II System (Arcturus Engineering, Sunnyvale, CA).
Recovered cells were suspended in 50 L of DNA extrac-
tion buffer (1 mmol/L EDTA; 10 mmol/L Tris, pH 8; 1%
Tween-20; and 1 mg/mL proteinase-K) and incubated at
50°C overnight, followed by 10 minutes at 95°C. Total
RNA from LCM cells or homogenized microdissected
samples was extracted using the Stratagene Absolutely
RNA Microprep kit (Agilent Technologies, Palo Alto, CA).
Nested-PCR Amplification of KLF6 Exon 2, Cloning,
and Sequencing
DNA solution (5L) wasmixed with 45L of High Fidelity
PCR Supermix (Invitrogen, San Diego, CA) and 100 mol/L
forward and reverse primers. First-round PCR product, 1
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(5=-CGGGCGCAATGTTATCTGTCCTTC-3=) and 2AR (5=-
AATGGGGTCGGAGGTAAA-3=) and 2BF (5=-AGCAGC-
GAATCCTCTGACAG-3=) and 2BR (5=-CCCTCCAGGG-
CTGGTGCA-3=) to spare exon 2 in two fragments of 400
and 422 bp, respectively; and 2ANF (5=-TCTGTC-
CTTCATTCTTGCAT-3=), 2ANR (5=-TTGGCCGTGGGA-
GAAAGTTC-3=), 2BNF (5=-CTCCCACGGCCAAGTTTAC-
3=), and 2BNR (5=-GTCCGCTGGTGTGCTTTCAA-3=) for
nested PCR. Nested-PCR amplicons were purified with the
QIAquick PCR Purification Kit (QIAGEN, Germantown, MD)
after insertion into the pCR2.1-TOPO DNA plasmid (Invitro-
gen); constructs were incubated overnight with Mach-1
competent cells and plated on LB Amp plates (Roche,
Indianapolis, IN) with 40 L of 40 mg/mL X-Gal at 37°C for
24 hours. Plasmids from positive clones12–18 were purified
with the QIAprep Spin Miniprep Kit (QIAGEN). The KLF6
insert was confirmed by PCR (30 cycles) and sequenced in
both directions with the nested-PCR primers using a 3730xl
DNA Analyzer (Applied Biosystems, Carlsbad, CA). DNA
sequence results were assembled using Sequencher soft-
ware version 4.2 (GeneCodes Corporation, Ann Arbor, MI)
and compared with the KLF6 GenBank DNA genomic se-
quence (AF284036). We defined a mutation as any BC
identified in both forward- and reverse-sequence products
in two or more clones per specimen and not present in its
NEC or any NP.
Analysis of Mutations
To distinguish driver from passenger somatic mis-
sense mutations, Cancer-specific High-throughput Anno-
tation of Somatic Mutations software (CHASM) was ap-
plied.15 A better-characterized spectrum of passenger
mutations of glioblastoma was used.16 The CHASM raw
score is the fraction of trees that classified the mutations
as a passenger; the null hypothesis (mutants are passen-
gers) was tested, and P values were corrected by multi-
ple testing (Benjamini-Hochberg false-discovery rate).
PolyPhen-2 software version 2.2.2 with the HumVar data
set was used to predict the impact of AA substitutions
due to missense mutations of KLF6 exon 2 on the struc-
ture and function of KLF6 proteins.17
KLF6 mRNA Analysis
RNA was obtained from 74 frozen specimens, including
25 HN primary PCs (88% Gleason score 6 and 12%
Gleason score 7), 21 primary hormone (androgen)–de-
prived PCs (HD-PCs) removed after 3 to 6 months of
neoadjuvant hormone therapy (31% Gleason score 6,
44% Gleason score 7, and 25% Gleason scores 8 and 9),
6 CRPC mets, and 22 NPs. Representative areas of PCs,
NP epithelia, and mets were obtained by LCM or micro-
dissection. RNA, extracted as previously described, was
reverse transcribed using random hexamers (Amersham-
Pharmacia Biotech, St. Albans, UK) using the High Ca-
pacity cDNA Reverse Transcription Kit (Applied Biosys-
tems). The cDNA was amplified using the High Fidelity
PCR Supermix (Invitrogen) with KLF6-specific primers
(forward, 5=-GACATGGACGTGCTCCCCAT-3=; and re-verse, 5=-ATGCCGCTTCTTACAGGA-3=) located at posi-
tion 184 in exon 1 and 225 in exon 4, respectively. The
1030-bp amplicon was cloned, as previously described,
and 12 clones per case were sequenced and analyzed,
as previously described, except for comparison to the
KLF6 GenBank mRNA sequence (NM001300). Scan-
Prosite software (Swiss Institute of Bioinformatics) was
used to predict the AA sequence and changes in func-
tional ZF domains. The prevalence of the different KLF6
SVs was assessed by the number of clones with each SV
in each specimen.
Cell Lines
HEK-293 and LNCaP cells (ATCC 2009, Manassas, VA)
were grown in Eagle’s minimum essential medium (Sig-
ma-Aldrich, St. Louis, MO) and RPMI 1640 medium sup-
plemented with 10% fetal bovine serum (FBS), respec-
tively. For MTT assays, 4  103 LNCaP cells grown with
10% FBS or charcoal-stripped FBS were transfected with
0.2 g of pFLAG-CMV-2 Expression Vector (Sigma-Al-
drich) containing wt- or SV-KLF6 and analyzed 5 days
after transfection in three independent experiments.18
Luciferase Transactivation and Immunoblotting
HEK-293, 5  104 cells per well, was transfected with DNA
containing p21 reporter construct,19 pFLAG-CMV-2 vector
containing wt-KLF6 or the test SV, and the pRL-SV40 Lucifer-
ase Vector (Promega,Madison,WI) to normalize transfections.
At 48 hours, whole cell protein extracts were quantified by the
dual-luciferase system (Promega), and 20 g was used for
12% SDS-PAGE and transfer to a nitrocellulose membrane18
to characterize wt-KLF6 and SVs by anti-KLF6 (sc-134374;
Santa Cruz), anti-FLAG (F3165; Sigma-Aldrich), and second-
ary antibodies.
Statistical Analysis
Continuous variables were described by the mean and
SD and compared by the Student’s t-test. Categorical
variables were described by counts and percentages
and were compared with the 2 or Fisher’s statistical
tests. All tests were two sided; P  0.05 indicated statis-
tical significance (IBM SPSS Statistics 19, Chicago, IL).
Results
KLF6 Exon 2 Mutation Analysis
KLF6 mutation analysis was focused on exon 2, because
80% of previously identified mutations were located
there.6,7 We identified 26 BCs in 20 of 81 PC specimens,
including 18 (26%) of 70 primary PCs and 2 (29%) of 7
HN-LN mets; 0 BCs were detected in 7 NPs (Table 1). All
BC-positive PC specimens were FFPE, whereas all BC-
negative specimens, including four CRPC mets and
seven NPs, were fresh frozen, raising the question of
whether the detection of BC could be related to FFPE
processing. However, BCs were only present in 1 (6%) of
us; S, s
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primary PCs (P  0.11).
Of the 26 BCs, 14 were nonsynonymous mutations (13
missense and 1 nonsense) and 12 were synonymous or
silent mutations. The 14 nonsynonymous mutations af-
fected 13 cases, corresponding to 11 primary PCs and 2
HN-LN mets. The 12 synonymous mutations occurred in
9 primary PCs, 1 HN-LN met, and 1 NEC with a BC. Thus,
the incidence of potentially dysfunctional nonsynony-
mous mutations was 14 of 81 in PC specimens versus 0
of 25 in normal control specimens (P  0.04). A previ-
ously reported germline DNA polymorphism in intron 1
(27 GA) was not detected in any specimen.6
We further analyzed the potential effect of the 13 mis-
sense mutations and their corresponding AA substitu-
tions on KLF6 function by applying two bioinformatics
tools. First, CHASM software was applied to determine
whether the BC could be classified as driver or passen-
ger mutations.15 Three missense mutations (C48R,
P148S, and K174R) distributed among three primary PCs
and one HN-LN met achieved the significance level for a
driver mutation (P  0.05, Benjamini-Hochberg false-
discovery rate  0.2; Table 1). Second, the PolyPhen-2
Table 1. Distribution of PC Cases with BCs in Two or More Clon
Case
no.*
BC in KLF6
gene
Exon 2
position
AA
change NS or S
CHAS
score
1 T3089C 40 C48R NS 0.486
2 T3118C 69 F57F S
3 T3147C 98 I67T NS 0.642
4 T3147C 98 I67T NS 0.642
2 A3149G 100 I68V NS 0.54
5 G3354T 305 S136I NS 0.532
6 C3390T 341 P148S NS 0.372
4 T3400C 351 S151S S
7 G3401A 352 P152P S
8 C3407T 358 L154L S
9 A3410G 361 S155G NS 0.66
10 C3428T 379 L161L S
4 C3428T 379 L161L S
11 G3432A 383 W162stop NS
12 G3434A 385 G163S NS 0.838
13 A3468G 419 K174R NS 0.298
14 A3468G 419 K174R NS 0.298
15 C3478T 429 S177S S
16 A3482G 433 T179A NS 0.568
17 G3487A 438 S180S S
13 G3490A 441 G181G S
13 A3504G 455 K186E NS 0.55
18 A3533T 484 R196W NS 0.61
19 G3550A 501 R201R S
2 C3556T 507 H203H S
20 T3577C 528 V210V S
Distribution of cases with BCs in two or more clones and effect on AA
the prediction of driver/passenger NS missense mutations. PolyPhen-2 pr
(damaging  probably damaging  possibly damaging  benign). Mut
in NEC or NP specimens.
*The case numbers that are duplicated mean for example, that patien
is organized according to the sequential location of the BC in the KLF6
†Clones that showed the specific BC in both DNA strands.
BHFDR, Benjamini-Hochberg false-discovery rate; NS, nonsynonymosoftware was applied to determine whether the AA sub-stitutions that resulted from the 13 missense mutations
affected the structure and function of the KLF6 protein.
By this analysis, two missense mutations in two primary
PCs were probably damaging (P148S and R196W), and
a recurrent missense mutation in one primary PC and one
HN-LN met was possibly damaging (K174R). The remain-
ing nine missense mutations were classified as benign.
Combined analysis indicated that only two of the three
putative driver mutations (P148S and K174R) coded for a
significant change in KLF6 structure and were, therefore,
likely true drivers. In addition, one primary PC harbored a
nonsense mutation (W162stop), which predicted a trun-
cated KLF6 protein lacking the entire ZF-containing DBD
with consequent loss of function (see Supplemental Fig-
ure S1 at http://ajp.amjpathol.org). Thus, only 3 (4%) of 81
PC cases harbored nonsynonymous mutations predicted
to be dysfunctional.
Identification and Characterization of KLF6 SVs
Types of KLF6 SVs in NP and PC Specimens
We analyzed fresh-frozen specimens from 22 NPs and
value BHFDR PolyPhen-2
No. of
clones†
Tumor
group
Gleason
score
.046 0.15 Benign 2 Primary 6
2 Primary 10
.118 0.15 Benign 2 Primary 6
.118 0.15 Benign 2 Primary 6
.065 0.15 Benign 2 Primary 10
.063 0.15 Benign 2 Primary 10
.025 0.15 Probably
damaging
2 Primary 6
2 Primary 6
2 Primary 6
2 Primary 6
.134 0.15 Benign 2 Primary 6
2 Primary 6
2 NEC
Damaging 2 Met
.496 0.5 Benign 2 Primary 6
.014 0.15 Possibly
damaging
4 Met
.014 0.15 Possibly
damaging
2 Primary 6
2 Primary 8
.077 0.15 Benign 2 Primary 8
7 Primary 6
4 Met
.068 0.15 Benign 2 Met
.098 0.15 Probably
damaging
2 Primary 6
9 Primary 8
2 Primary 10
2 Primary 6
nce of KLF6 exon 2. CHASM raw score, P value, and BHFDR values for
of the effect of NS missense mutations on protein structure and function
s defined by a BC present in two or more of 12 clones and not present
r 2 has the T3118C mutation and the A3149G and the C3556T. The table
ynonymous.es
M
P
0
0
0
0
0
0
0
0
0
0
0
0
0
seque
ediction
ation wa
t numbe
gene.52 PCs for KLF6 SVs and identified 16 different spliced
rotein do
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described in PCs,11 and 13 SVs were novel. Figure 1B
shows the predicted protein and mol.wt. of wt-KLF6 and
the SV transcripts. Fourteen of the SVs affected the ZF
DBD to different extents. Ten SVs (1, 4 to 7, 10 to 12, 15,
and 16) lack the entire DBD because of loss of all three
ZFs encoded by KLF6 exons 2 to 4 (Figure 1; see also
Supplemental Figure S2 at http://ajp.amjpathol.org). Four
SVs had partial loss of the DBD: SV2 and SV8 lacked ZF1
but had an intact ZF2 and ZF3, SV3 lacked ZF2 and ZF3
but had an intact ZF1, and SV9 lacked ZF1 and ZF2 but
preserved ZF3. In seven SVs (1, 3, 5, 7, 11, 12, and 15),
the DBD was affected by a change in the reading frame
that introduced an early stop codon and generated a
unique carboxy-terminal peptide. In the remaining nine
SVs, the reading frame was not changed but there was a
shortened RNA that encoded a truncated protein. In
SV13 and SV14, the ZF-DBD was uniquely intact, but the
TAD was shortened, markedly so in SV14. Overall, the
predicted protein products of the SVs ranged from 41AA
(5 kDa) to 222 AA (25 kDa) compared with 283 AA (32
Figure 1. KLF6 gene, alternative splicing, and protein prediction. A: Diagram
human prostate and prostate cancer tissues. Exon length and location of th
product of the different SVs. Wt-KLF6 has an N-terminal TAD and three ZFs
transcriptional activity of the KLF6 protein, and ZFs are responsible for the sp
of the TAD extends from AA 1 to 201, ZF1 from Cys202 to His224 (gray box)
double boxes). SVs 1 to 16 are represented with the different changes in the p
localization signal.kDa) for wt-KLF6.To identify the splice sites for each SV, we analyzed
the mRNA cDNA sequence and determined that there
were five different GT cryptic splice donor sites in exon 2
for SVs 1, 2, 4 to 7, and 9; and three different GC cryptic
splice donor sites for SVs 10, 14, and 15. SV3 skipped
exon 3, and SV11 contained a cryptic exon of 66 nucle-
otides mapped to a region of intron 1, previously desig-
nated exon 1a.20 To determine whether the use of the
cryptic splice donor sites was due to mutations in the
KLF6 consensus splice sites, we performed DNA se-
quencing in 21 specimens expressing different SVs. No
BCs were identified in the consensus splice sites flanking
exons 2 and 3 in 5 NPs, 10 HN mets, and 6 CRPC mets.
To assess the size of the proteins encoded by the more
representative KLF6 transcripts, wt-KLF6 or SV1 through
SV4 and SV14 were cloned into a pFLAG-CMV-2 expres-
sion vector and transiently transfected into HEK-293
cells. KLF6 and FLAG antibodies were used to measure
the mol.wt. of the proteins by using Western blot analysis.
In agreement with the software prediction, wt-KLF6 had
the highest mol.wt. (32 kDa), followed by SV2 (27 kDa),
6 gene and alternative SVs observed in microdissected epithelium of normal
odon (1098) are shown. B: wt-KLF6 protein domains and predicted protein
ZF3) at the end of the C-terminal domain. The TAD is responsible for the
NA binding with the guanine-rich core promoter elements. The AA sequence
m Arg231 to Thr255 (black box), and ZF3 from Cys262 to Leu283 (light gray
mains and novel AA carboxyl domains [lightest box (asterisk)]. NLS, nuclearof KLF
e stop c
(ZF1 to
ecific D
, ZF2 froSV4 and SV1 (21 kDa), and SV14 (18 kDa) (see Supple-
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the effect of loss of ZF and shortening of the TAD on the
transcriptional activity of KLF6 isoforms, we prepared
constructs of SVs that lack all three ZFs but differ in
length of the TAD (SVs 1, 4, 11, and 12), SVs that lack ZF2
and ZF3 (SV3) or only ZF1 (SV2) with an almost intact
TAD, and SVs with an intact DBD (ZFs 1 to 3) but a
shortened TAD (SV14). The transcriptional activity of
these SVs was measured in cotransfection experiments
with a p21 luciferase reporter (Figure 2). SVs lacking
either ZF1 or ZFs 2 to 3, but with an intact TAD, had
80% decreased activity compared with wt-KLF6 (P 
0.05). In contrast, SV14 with intact ZFs 1 to 3 preserved
the transcriptional activity, despite a major loss of the
TAD (P  0.67). These results demonstrated that the
integrity of all ZFs was essential for the activation of p21
transcription by KLF6.
Distribution of KLF6 SV Expression among NP and
PC Specimens
As shown in Table 2, SVs were shared between NP
and PC (SVs 1 to 4), three SVs were found exclusively in
NP (SVs 13, 14, and 16), and nine SVs were found ex-
clusively in PC (SVs 5 to 12 and 15). Among the shared
SVs, the most frequently observed in PC versus NP tis-
sues were SV1 (38.5% versus 18.2%; P  0.09), SV3
(34.6% versus 4.5%; P  0.007), and SV2 (21.2% versus
13.6%; P  0.53). The remaining 13 SVs were distributed
in 10% of the cases: 9 in 16 PCs, 3 in 3 NPs, and 1
(SV4) in both NP2 and PC5 tissues. Compared with NP,
the PC specimens had more cases with at least one SV
[39 (75%) of 52 versus 10 (45.5%) of 22; P  0.01], had
accumulated two or more different types of SVs per spec-
imen [18 (34.6%) of 52 versus 2 (9.1%) of 22; P  0.02],
and had25% of the clones expressing SVs [19 (49%) of
39 versus 1 (10%) of 10; P  0.03]. In summary, these
data indicated that alternative KLF6 splicing was a fre-
quent event in NP, and that it increases significantly
Figure 2. Transcriptional activity of wt-KLF6 and SVs measured by transac-
tivation of the p21 reporter relative to empty vector. The mean values and
SDs of three independent experiment are represented; statistically significant
differences compared with wt-KLF6 are determined by the Student’s t-test.
*P  0.05.in PC.Distribution of KLF6 SVs among PC Tissues
according to Hormone Treatment
To determine whether the higher incidence of alterna-
tive SVs in PC tissues might be conditioned by hormonal
therapy, we assessed the distribution of SVs among the
21 HD-PCs, 25 HN-PCs, and 6 CRPC mets. As shown in
Tables 3 and 4, the most frequently observed SVs in
HD-PC versus HN-PC were as follows: SV1, 16 (76%) ajp
of 21 versus 3 (12%) of 25 (P  0.001); SV2, 7 (33%) of
21 versus 3 (12%) of 25 (P  0.05); and SV3, 7 (33%) of
21 versus 9 (36%) of 25 (P  0.05). SV4 was only de-
tected in HD-PC [4 (19%) of 21; P 0.04]. The remaining
nine SVs were not observed in more than three PC cases
each. There were seven different SVs identified in four of
six CRPC mets, and five were also present in a primary
PC; SV11 was exclusive to one CRPC. Notably, SV3 was
the only SV more frequently expressed in HN-PC (36%)
than NP (4.5%; P  0.01); also, it was detected in more
than one CRPC met.
Compared with HN-PC, significantly more HD-PC
cases had at least one SV [19 (90.5%) of 21 versus 16
(64%) of 25; P 0.04] and accumulated multiple SVs [12
(57%) of 21 versus 3 (12%) of 25; P  0.001] and 25%
of the clones expressing SVs [12 (63%) of 19 versus 4
(25%) of 16; P  0.02]. Correspondingly, cases that
expressed wt-KLF6 alone were more frequent in HN-PC
than in HD-PC (36% versus 9.5%).
In summary, these results indicated that PC tissues
recovered after androgen deprivation therapy (HD-PCs)
have an increased incidence and greater diversity of
alternative SVs than NP or HN-PCs.
Table 2. Distribution of SVs in NP and PC Specimens
KLF6
PC specimens
(n  52)
NP
(n  22) P value
SV1 20 (38.5) 4 (18.2) 0.089
SV2 11 (21.2) 3 (13.6) 0.534
SV3 18 (34.6) 1 (4.5) 0.007*
SV4 5 (9.6) 2 (9.1) 1
SV5 3 (5.8) 0 (0.0) 0.55
SV6 1 (1.9) 0 (0.0) 1
SV7 1 (1.9) 0 (0.0) 1
SV8 1 (1.9) 0 (0.0) 1
SV9 1 (1.9) 0 (0.0) 1
SV10 2 (3.8) 0 (0.0) 1
SV11 1 (1.9) 0 (0.0) 1
SV12 4 (7.7) 0 (0.0) 0.311
SV13 0 (0.0) 1 (4.5) 0.297
SV14 0 (0.0) 1 (4.5) 0.297
SV15 2 (3.8) 0 (0.0) 1
SV16 0 (0.0) 1 (4.5) 0.297
1 SV 39 (75.0) 10 (45.5) 0.014*
2 SVs 18 (34.6) 2 (9.1) 0.024*
3 SVs 8 (15.4) 1 (4.5) 0.265
SVs 25% clones† 19 (49) 1 (10) 0.034*
Proportion of cases bearing one or more different SVs (one, two, or
three or more) and having 25% of the clones with any type of SV.*Significantly different.
†n  39 for PC specimens and n  10 for NP.
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Function
To evaluate the distribution of SVs by predicted func-
tional activity among the tissue types, we stratified the
cases into two groups: those with normal KLF6 function
by expression of only wt-KLF6 or SVs that preserved all
three ZFs (SVs 13 and 14) and those with nonfunctional
KLF6 because of expression of SV with loss of all three
ZFs [ZFs 2 and 3 (SV3) or ZF1 (SVs 2 and 8)] (Table 4).
We then assessed the proportion of cases with nonfunc-
tional KLF6 in NP versus PC through different clinical
stages of PC progression. As shown in Table 4, the pro-
portion of cases with nonfunctional SVs was significantly
higher in PC than NP: 39 (75%) of 52 and 8 (36.3%) of 22,
respectively (P  0.002). The proportion of nonfunctional
Table 3. Distribution of SVs in NP and PC Tissues from HN, HD
Variable HD HN Mets
KLF6 n  21 n  25 n  6
SV1 16 (76.2) 3 (12.0) 1 (16.7
SV2 7 (33.3) 3 (12.0) 1 (16.7
SV3 7 (33.3) 9 (36.0) 2 (33.3
SV4 4 (19.0) 0 (0.0) 1 (16.7
SV5 3 (14.3) 0 (0.0) 0 (0.0)
SV6 1 (4.8) 0 (0.0) 0 (0.0)
SV7 1 (4.8) 0 (0.0) 0 (0.0)
SV8 1 (4.8) 0 (0.0) 0 (0.0)
SV9 1 (4.8) 0 (0.0) 0 (0.0)
SV10 0 (0.0) 1 (4.0) 1 (16.7
SV11 0 (0.0) 0 (0.0) 1 (16.7
SV12 1 (4.8) 2 (8.0) 1 (16.7
SV13 0 (0.0) 0 (0.0) 0 (0.0)
SV14 0 (0.0) 0 (0.0) 0 (0.0)
SV15 1 (4.8) 1 (4.0) 0 (0.0)
SV16 0 (0.0) 0 (0.0) 0 (0.0)
1 SV 19 (90.5) 16 (64.0) 4 (66.7
2 SV 12 (57.1) 3 (12.0) 3 (50.0
3 SV 8 (38.1) 0 (0.0) 0 (0.0)
KLF6 SV n  19 n  16 n  4
25% clones 12 (63) 4 (25) 3 (75)
Distribution of SVs in NP and PC tissues from HN, HD, and castration
or three or more) and having 25% of the clones with any type of SV.
*Significantly different.
HD, hormone deprived; HN, hormone naïve.
Table 4. Distribution of SVs according to Function of the
Predicted KLF6 Protein
Tissue specimens Nonfunctional (%) Functional (%)
Tumor 39/52 (75.0) 13/52 (25.0)
NP 8/22 (36.3) 14/22 (63.6)
Hormone naïve 16/25 (64.0) 9/25 (36.0)
Hormone deprived 19/21 (90.5) 2/21 (9.5)
Distribution of KLF6 splice variants (SV) according to function of the
predicted KLF6 protein in prostate cancer, NP tissues, hormone-naïve
and hormone deprived tissues. The comparison of the proportion of cases
with non-functional KLF6 SV referred to normal KLF6 function (wt-KLF6,
SV13 and SV14) is significantly higher in tumor vs. normal prostate spec-
imens (P  0.002) and hormone deprived vs hormone naïve specimens
(P  0.036). The proportion of hormone deprived cases carrying non-
functional KLF6 SV compared to normal prostate specimens reaches the
statistical significance (P  0.0002) while hormone naïve does not (P 
0.059).KLF6 SVs was also significantly higher in HD-PC than
HN-PC tissues [19 (90.5%) of 21 versus 16 (64%) of 25;
P  0.036].
KLF6 Effect on Proliferation and Survival of
Human PC Progression
The progressive enrichment of dysfunctional KLF6 SVs
from NP, HN-PC, to HD-PC led us to postulate that in-
creased splicing with loss of KLF6 function first enabled
the emergence of PC and subsequently supported the
survival of hormone-resistant PC under the selective
pressure of androgen deprivation. As a first step in test-
ing this hypothesis, we studied the effect of forced ex-
pression of nonfunctional KLF6 SV1 through SV4 com-
pared with wt-KLF6 in androgen-dependent LNCaP cells
in the presence or absence of androgens. As shown in
Figure 3, compared with forced expression of wt-KLF6,
nonfunctional SV expression increased the growth of
LNCaP cells by 35% (P  0.05) in androgen-deprived
conditions, whereas the growth was not affected in the
presence of androgens. Thus, these results provided
support for our hypothesis that KLF6 splicing may play a
role in the establishment of androgen-independent PC.
Discussion
In this study, we performed an in-depth analysis of two
mechanisms of KLF6 inactivation, mutations in exon 2
and expression of alternative mRNA SVs, to assess their
potential roles in clinical PC progression. We used LCM
astration-Resistant Mets
NP
P value
HD vs HN HD vs NP HN vs NP
n  22
4 (18.2) 0.0001* 0.0001* 0.69
3 (13.6) 0.15 0.162 1
1 (4.5) 0.85 0.021* 0.012*
2 (9.1) 0.037* 0.412 0.214
0 (0.0) 0.088 0.108
0 (0.0) 0.457 0.488
0 (0.0) 0.457 0.488
0 (0.0) 0.457 0.488
0 (0.0) 0.457 0.488
0 (0.0) 1 1
0 (0.0)
0 (0.0) 1 0.488 0.491
1 (4.5) 1 0.468
1 (4.5) 1 0.468
0 (0.0) 1 0.488 1
1 (4.5) 1 0.468
10 (45.5) 0.036* 0.002* 0.202
2 (9.1) 0.001* 0.001* 1
1 (4.5) 0.001* 0.009* 0.468
n  10
1 (10) 0.024* 0.008* 0.617
t Mets. Proportion of cases bearing one or more different SVs (one, two,, and C
)
)
)
)
)
)
)
)
)
-resistantechnology to enrich for PC cells and to increase the
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mRNA SVs over methods used in previous studies. To
assess the relationship of the KLF6 aberrations to dis-
ease progression, we studied a relatively large number of
PC specimens covering the spectrum of the disease in
comparison to NP control specimens.
We focused our study of KLF6 mutations on exon 2,
because this is the site of 80% of previously reported
mutations. Our finding of a 24.6% incidence of potentially
mutagenic BCs in 81 PC cases is an intermediate value
compared with four previous reports in which the inci-
dence ranged from 0% to 50% (see Supplemental Table
S1 at http://ajp.amjpathol.org).6–9 In the two most recent
reports, Muhlbauer et al8 and Agell et al9 found no exon
2 BC in 32 and 103 PC specimens, respectively, and
these investigators suggested that previous findings of a
significant incidence of these mutations in PC are likely
due to technical artifacts related to Taq polymerase-gen-
erated errors during PCR amplification in FFPE speci-
mens. However, both of these studies used direct PCR
sequencing of genomic DNA, which has limited sensitiv-
ity to detect BC (one or fewer in eight for homozygous or
hemizygous mutations and one or fewer in four for
heterozygous mutations). Thus, these investigations
might have overlooked some BC at the level detected in
our study using cloned PCR products (two or more BCs
per 12 clones) or in the initial study by Narla et al6 (two or
more BCs per six clones). At least two observations sup-
port the likelihood that many of the reported BCs are not
sequencing artifacts. First, in our report and the two other
exon 2 BC-positive reports (see Supplemental Table S1
at http://ajp.amjpathol.org), only one BC was found in 78
specimen-matched FFPE normal tissue controls (35
NECs and 43 matched nonneoplastic cells). Second,
both Narla et al6 and Chen et al7 sequenced all of KLF6
exons 1 to 4, and found 80% of the BC in exon 2, which
represents only 40% of the total nucleotides sequenced.
Hence, the BC did not occur at random, as might be
expected for artifacts. Agell et al9 found that 70% of their
unconfirmed BCs, which were regarded as artifacts, in-
volved insertion of an adenine related to denaturation of
DNA at AT-rich regions in formaldehyde-fixed tissues.However, KLF6 exon 2 does not contain an AT-rich tract,
and, in our study, the maximum possible fraction of ad-
enine substitution artifacts was 50% (the predicted inci-
dence for a random substitution). We conclude that most
BCs reported in our study are likely true changes, and
that the reported differences in the incidences of KLF6
BC in primary PC are considerably affected by differ-
ences in detection criteria and sensitivity. Further studies
using more advanced, reiterative sequencing methods in
larger sample sets may provide a more precise estimate
of BC in PC.
Assuming the validity of KLF6 BC in PC in our study,
their significance might be questioned. One consider-
ation is the penetrance of the BC in the tumor cell pop-
ulation. In 17 of 20 PC cases, the minimum of 2 of 12
BC-positive clones was detected, which is one third of
the predicted number for a pure BC-harboring heterozy-
gous tumor cell population. There are essentially three
possibilities that could account for the minority incidence:
the presence of DNA from coresident normal cells heter-
ogeneity related to several tumor foci typically sampled
by LCM to provide sufficient DNA for analysis, or heter-
ogeneity within all tumor sampled because of clonal vari-
ation. Although our study does not discriminate between
these possibilities, the tumor cell enrichment achieved by
LCM and our finding of a high incidence of aberrant SVs
exclusively in tumor specimens (described later) may
favor the presence of some heterogeneity. A second
consideration is the nature of the BC. In our study, 14 of
26 BCs produced an AA change, a requisite for a poten-
tial functional effect (Table 1). One of these nonsynony-
mous BCs produced a nonsense mutation (W162stop),
encoding a truncated protein lacking the entire ZF-DBD.
The other 13 nonsynonymous BCs produced missense
mutations, which we analyzed for potential functional sig-
nificance using two bioinformatics tools. The CHASM tool
predicted three potential driver mutations: C48R, P148S,
and K174R. The PolyPhen-2 tool, which assesses the
effect based on protein structural changes, also identi-
fied P148S and K174R as probably or possibly damag-
ing, but found C48R to be benign; it also identified
Figure 3. Cell growth measured by MTT assays of
LNCaP cells with forced expression of wt-KLF or the
nonfunctional KLF6 SVs (SV1, SV2, SV3, and SV4)
under the stress of androgen deprivation and base-
line growth conditions. The mean values and SDs of
three independent experiments are represented;
statistically significant differences compared with
wt-KLF6 are determined by the Student’s t-test.
*P  0.05.R196W as probably damaging, although CHASM did not
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mous mutations have properties consistent with a driving
role in PC: W162stop, P148S, and K174R. We also used
these bioinformatics tools to assess the 23 missense
mutations identified by Narla et al.6 Only two missense
mutations were identified by CHASM as driver mutations:
W64R, which decreased transcriptional activation of a
p21 reporter by KLF66; and L217S. In addition, Narla et
al6 identified the nonsense mutation, S137X; and a third
early exon 2 nonsense mutation, Q160X, was reported by
Bar-Shira et al21 as a germline mutation in a patient with
PC. Including our cross-report analysis, the only recur-
rent nonsynonymous mutations are in this study: the pre-
viously mentioned K174R driver in one primary PC and
one metastasis and I67T, evaluated as a benign non-
driver (Table 1). Based on this overall analysis, we con-
clude that nonsynonymous mutations with likely patho-
logical relevance only occur in10% of patients with PC,
although we cannot exclude the possible significance of
other nonsynonymous mutations.
In contrast to the low incidence of nonsynonymous
mutations in PC, we found at least one alternative SV of
KLF6 mRNA in 75% of PCs. We also found a single
alternative SV in 46% of NPs, suggesting that expression
of some alternative KLF6 SVs is common in NP. However,
both the number and variety of SVs were markedly in-
creased in PC compared with NP (Table 2). This increase
includes the expression level of the SV in PC, as mea-
sured by the fraction of mRNA-derived recombinant
clones containing SVs. Furthermore, 90% of more ad-
vanced PCs derived from patients treated with hormone
deprivation therapy had SV compared with 65% of less
advanced HN-PCs (Table 3). Indeed, the major increase
in SVs is noted between HD-PC (primarily derived from
residual, localized PC) and HN-PC, suggesting that the
SVs are associated with disease progression to andro-
gen independence. Nevertheless, these HD-PCs had not
developed clinical castration resistance; hence, it is also
of interest that there was no apparent difference in the SV
profile of HD-PCs and CRPC mets, which presumably
have taken a further step in disease progression, al-
though the few CRPC mets available6 limited this assess-
ment (Table 3).
Sixteen different SVs were identified in this study (Fig-
ure 1). The SVs were identified with varying frequencies:
8 in a single specimen, 4 in 2 to 4 specimens, and 4 in 7
to 24 specimens (Table 2). Three of the single-specimen
SVs were from NPs, whereas the SVs identified in two or
more specimens were predominantly or entirely from
PCs. Fourteen SVs resulted in loss of one or more ZFs
involved in the DNA binding of KLF6, including complete
loss of ZF1 in 13 SVs. We determined that, unlike wt-
KLF6, all SVs lacking ZF1 were unable to activate tran-
scription on a p21 gene promoter (Figure 2). The single
SV lacking ZF1 alone (SV3) was also functionally inactive.
These results are in agreement with a previous report
that at least ZF1 and ZF2 are needed to retain the
nuclear localization and tumor suppressor function of
KLF6.5 Alternatively, an SV that retained all three ZFs
but had an extensive deletion of the TAD (SV14) was
functionally active. Notably, the two SVs that retainedthe ZFs (SV13 and SV14) were derived from NP, con-
sistent with the involvement of alternative splicing of
multiexon genes in normal cells, under physiological
conditions to generate proteome diversity.22 Con-
versely, altered regulation of splicing and the use of
cryptic splice sites are commonly observed in tumori-
genesis to generate aberrant mRNAs and defective
protein isoforms that compete with wt proteins or that
distort their normal function.23 Thus, it is of interest that
all SVs were nonfunctional in the 75% of PC specimens
harboring SV.
Based on the differences in the incidences of nonfunc-
tional SVs in HD-PC and HN-PC, we hypothesized that
aberrant splicing of KLF6 mRNA is enhanced by andro-
gen deprivation therapy and may serve as an additional
mechanism to the multiple events involved in the devel-
opment of resistance to hormone therapy. As a prelimi-
nary test of this hypothesis, we forced the expression of
four different nonfunctional KLF6 SVs (SV1 to SV4) in
androgen-dependent LNCaP cells, and we found that
expression of these SVs significantly increased the rate of
LNCaP cell growth only under androgen-deprived culture
conditions (Figure 3). These results differ from those of a
previous report that forced expression of SV1 in andro-
gen-independent PC3 cells, leading to increased prolif-
eration in non–androgen-depleted conditions.10 To-
gether, these two observations could reflect a primary
role of SVs in fostering androgen-dependent PC cell sur-
vival during androgen deprivation and a continuing com-
plementary role of the SVs with additionally acquired
genetic abnormalities in fully androgen/castration-resis-
tant PC cells. Although further experiments will be re-
quired to test our hypothesis, these in vitro results in an
androgen-dependent PC model and our analysis of hu-
man PC specimens represent the first report to link KLF6
SV to hormone therapy resistance. These observations
are analogous to other recent findings of a functional role
attributed to alternative SVs in resistance mechanisms in
cancer, including androgen receptor SVs in the develop-
ment of resistance to androgen deprivation and anti-
androgens in PC24 and in the development of resistance
to the RAF inhibitor, vemurafinib, by isoforms of BRAF in
melanoma.25 Finally, because we did not find any muta-
tions in consensus splice sites, but rather that the aber-
rant splicing is the result of activation of cryptic splice
sites in exons 2 and 3, the increase in expression of
nonfunctional KLF6 SVs could be the result of an under-
lying disturbance of the splicing machinery, a trans
mechanism that can simultaneously alter the expression
of multiple genes during disease progression, as recently
reported in other neoplasias.26,27
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